In what represents the first Patent Cooperation Treaty filing published in the name of London, U.K.-based Abtrace Ltd., the company’s co-founder and chief executive officer, Umar Naeem Ahmad, collaborates with Xavier Monnet – professor of intensive care at Assistance Publique - Hôpitaux de Paris (APHP) Université Paris-Saclay – on the design of a fluid delivery system for delivering intravenous fluid therapy to a patient.
With a landmark U.K. approval in hand for Casgevy (exagamglogene autotemcel [exa-cel]) to treat sickle cell disease and transfusion-dependent beta thalassemia, Crispr Therapeutics AG and partner Vertex Therapeutics Inc. are turning their attention to the PDUFA dates set by the U.S. FDA for the treatment in both conditions.
Gilde Healthcare Partners BV finally closed its Venture & Growth VI fund after raising €740 million (US$803 million) in commitments. The venture capital firm added €140 million to the €600 million unveiled earlier in the year due to strong interest from institutional investors.
Senior leaders and investors in the health care sector expect mergers and acquisitions (M&A) activity to continue to pick up next year but this will be corporate led rather than private equity, according to a report by global investment bank Jefferies.
Siemens Healthineers AG appears to be committed to its Diagnostics business after Jochen Schmitz, CFO, pushed back at rumors speculating that the German company was looking at options for the underperforming segment, including a sale.
Serial biotech-founding venture fund Flagship Pioneering Inc., most noted for launching Moderna Inc. in 2012, is crossing into the Asia Pacific (APAC) region and setting up a regional office in Singapore, a move that comes on the heels of its entry into the U.K. earlier this year.
Senior leaders and investors in the health care sector expect mergers and acquisitions (M&A) activity to continue to pick up next year but this will be corporate led rather than private equity, according to a report by global investment bank Jefferies. At the same time, many executives remained concerned about the lack of funding in the sector as it was identified as the number one threat.
In the following years, 2023 may come to be seen in medical device circles as the year of artificial intelligence (AI), but that doesn’t mean that 2023 will be seen as the year of regulatory clarity for AI.
Researchers have for the first time used human neural stem cells to print 3D brain tissues that mimic the architecture of the brain’s outer layer, the cerebral cortex. This breakthrough technique, developed by a team from the U.K.’s University of Oxford, could one day be used to provide tailored repairs to the millions of people who suffer from severe brain injuries, for which there is no effective treatment.
The funding environment continues to be challenging for companies in the health care sector, and even more so for early-stage med-tech companies, delegates heard at the LSX Investival Showcase in London. Med-tech companies were told that they had to be lean, constantly work on building relationships with investors and not to give up because there is money out there for innovative technologies that can save people’s lives.